Journal of Shanghai Jiao Tong University (Medical Science) >

2026 , Vol. 46 >Issue 3: 377 - 384

DOI: https://doi.org/10.3969/j.issn.1674-8115.2026.03.012

Review

Research advances in nanomaterials in cardiac fibrosis repair: from precision therapy to tissue remodeling

  • Xu Rui ,
  • Guo Jiacheng ,
  • Xie Shiyao ,
  • Han Deheng ,
  • Yue Xiuqin
Expand
  • 1.Department of Anesthesia and Perioperative Medicine, The First Affiliated Hospital of Henan Medical University, Weihui 453100, China
    2.Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
    3.Key Laboratory of Cardiac Injury and Repair of Henan Province, Zhengzhou 450052, China
    4.State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou 450001, China
Yue Xiuqin, E-mail: xiuqinyue@163.com.

Received date: 2025-09-07

  Accepted date: 2025-11-27

  Online published: 2026-03-30

Supported by

National Natural Science Foundation of China(82400336);Joint Construction Project of Henan Provincial Medical Science and Technology Research Program(LHGJ20230266)

Fold

Abstract

Cardiac fibrosis represents a common and pivotal pathological process in various cardiovascular diseases, significantly impeding cardiac functional recovery and adversely affecting long-term prognosis. Although conventional pharmacological agents, such as renin-angiotensin-aldosterone system inhibitors, exhibit certain anti-fibrotic effects, their insufficient targeting specificity and relatively confined mechanisms of action limit their capacity to achieve precise intervention in the core signaling pathways of cardiac fibrosis. In recent years, nanomaterials have demonstrated considerable potential in the precision treatment and tissue repair of cardiac fibrosis, owing to their unique size effects, tunable surface properties, and favorable biocompatibility. This review summarizes recent advances in nanomaterial-based approaches for cardiac fibrosis repair, with a focus on key strategies including precision delivery, intelligent controlled release, biomimetic functionality, and multifunctional integration. It further elucidates how nanomaterials modulate key signaling pathways at the molecular level and regulate the functions of critical cells, such as fibroblasts, immune cells, and endothelial cells, at the cellular level, thereby facilitating structural reconstruction and functional recovery at the tissue level, and ultimately achieving systematic repair from precision intervention to tissue remodeling. This article also discusses the current status and challenges associated with the clinical translation of nanomaterials in cardiovascular diseases, addressing issues such as biosafety, scalable production, and cross-species translation, and outlines future research directions. This review aims to provide a theoretical foundation and practical guidance for the development of effective and safe nano-therapeutic strategies against cardiac fibrosis.

Key words： cardiac fibrosis; nanomaterials; drug delivery; precision therapy; tissue remodeling

Cite this article

Xu Rui , Guo Jiacheng , Xie Shiyao , Han Deheng , Yue Xiuqin . Research advances in nanomaterials in cardiac fibrosis repair: from precision therapy to tissue remodeling[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026 , 46(3) : 377 -384 . DOI: 10.3969/j.issn.1674-8115.2026.03.012

References

[1] Zhang Y Z, Lin X Y, Chu Y, et al. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin Ⅱ-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling[J]. Cardiovasc Diabetol, 2021, 20(1): 121.
[2] Chen X F, Yang Q, Bai W L, et al. Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-β1/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure[J]. Front Pharmacol, 2022, 13: 873108.
[3] Chinnappa S, Maqbool A, Viswambharan H, et al. Beta blockade prevents cardiac morphological and molecular remodelling in experimental uremia[J]. Int J Mol Sci, 2023, 25(1): 373.
[4] Ibrahim W S, Ahmed H M S, Mahmoud A A A, et al. Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: comparative study with metformin[J]. Life Sci, 2021, 286: 120055.
[5] Cunningham J W, Claggett B L, O′Meara E, et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF[J]. J Am Coll Cardiol, 2020, 76(5): 503-514.
[6] Frangogiannis N G. Cardiac fibrosis[J]. Cardiovasc Res, 2021, 117(6): 1450-1488.
[7] Tie Y, Tang F, Peng D D, et al. TGF-β signal transduction: biology, function and therapy for diseases[J]. Mol Biomed, 2022, 3(1): 45.
[8] Zhang T T, Lei Q Q, He J, et al. Bestrophin3 deficiency in vascular smooth muscle cells activates MEKK2/3-MAPK signaling to trigger spontaneous aortic dissection[J]. Circulation, 2023, 148(7): 589-606.
[9] Cheng T H, Cheng P Y, Shih N L, et al. Involvement of reactive oxygen species in angiotensin Ⅱ-induced endothelin-1 gene expression in rat cardiac fibroblasts[J]. J Am Coll Cardiol, 2003, 42(10): 1845-1854.
[10] Bretherton R, Bugg D, Olszewski E, et al. Regulators of cardiac fibroblast cell state[J]. Matrix Biol, 2020, 91/92: 117-135.
[11] Nayakanti S R, Friedrich A, Sarode P, et al. Targeting Wnt-β-catenin-FOSL signaling ameliorates right ventricular remodeling[J]. Circ Res, 2023, 132(11): 1468-1485.
[12] Blyszczuk P, Müller-Edenborn B, Valenta T, et al. Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis[J]. Eur Heart J, 2017, 38(18): 1413-1425.
[13] Cho S, Rhee S, Madl C M, et al. Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis[J]. Nature, 2025, 642(8068): 766-775.
[14] Jiang H, Yang J J, Li T, et al. JAK/STAT3 signaling in cardiac fibrosis: a promising therapeutic target[J]. Front Pharmacol, 2024, 15: 1336102.
[15] Shi J L, Xiao P L, Liu X L, et al. Notch3 modulates cardiac fibroblast proliferation, apoptosis, and fibroblast to myofibroblast transition via negative regulation of the RhoA/ROCK/HIF1α axis[J]. Front Physiol, 2020, 11: 669.
[16] Senesi G, Lodrini A M, Mohammed S, et al. miR-24-3p secreted as extracellular vesicle cargo by cardiomyocytes inhibits fibrosis in human cardiac microtissues[J]. Cardiovasc Res, 2025, 121(1): 143-156.
[17] Li G Q, Shao Y H, Guo H C, et al. MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling[J]. Cardiovasc Res, 2022, 118(9): 2139-2151.
[18] Zhou J T, Tian G E, Quan Y, et al. The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1[J]. JCI Insight, 2023, 8(6): e160745.
[19] Wang X H, Chen T, Chen S Z, et al. STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation[J]. Signal Transduct Target Ther, 2025, 10(1): 136.
[20] Horwitz L D, Kaufman D, Keller M W, et al. Time course of coronary endothelial healing after injury due to ischemia and reperfusion[J]. Circulation, 1994, 90(5): 2439-2447.
[21] Prajnamitra R P, Chen H C, Lin C J, et al. Nanotechnology approaches in tackling cardiovascular diseases[J]. Molecules, 2019, 24(10): 2017.
[22] Wen J X, Guan Y, Niu H, et al. Targeting cardiac resident CCR2+ macrophage-secreted MCP-1 to attenuate inflammation after myocardial infarction[J]. Acta Biomater, 2024: S1742-S7061(24)00469-0.
[23] Chen W S, Liu L J, Tang M, et al. Type Ⅰ collagen-targeted liposome delivery of Serca2a modulates myocardium calcium homeostasis and reduces cardiac fibrosis induced by myocardial infarction[J]. Mater Today Bio, 2024, 28: 101162.
[24] Liu J, Zhuang T, Pi J J, et al. Endothelial forkhead box transcription factor P1 regulates pathological cardiac remodeling through transforming growth factor-β1-endothelin-1 signal pathway[J]. Circulation, 2019, 140(8): 665-680.
[25] Zhu D S, Liu S, Huang K, et al. Intrapericardial long non-coding RNA—Tcf21 antisense RNA inducing demethylation administration promotes cardiac repair[J]. Eur Heart J, 2023, 44(19): 1748-1760.
[26] Liang X Y, Zhang Y, Wang C D, et al. ROS-responsive death receptor 5 fusion protein nano-delivery system enhances myocardial ischemia-reperfusion injury protection[J]. Mater Today Bio, 2025, 32: 101899.
[27] Sullivan H L, Liang Y F, Worthington K, et al. Enzyme-responsive nanoparticles for the targeted delivery of an MMP inhibitor to acute myocardial infarction[J]. Biomacromolecules, 2023, 24(11): 4695-4704.
[28] Fatima M, Almalki W H, Khan T, et al. Harnessing the power of stimuli-responsive nanoparticles as an effective therapeutic drug delivery system[J]. Adv Mater, 2024, 36(24): e2312939.
[29] Zhao X L, Qin Y Z, Li B W, et al. Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis[J]. J Nanobiotechnology, 2025, 23(1): 10.
[30] Ji X Q, Meng Y B, Wang Q Y, et al. Cysteine-based redox-responsive nanoparticles for fibroblast-targeted drug delivery in the treatment of myocardial infarction[J]. ACS Nano, 2023, 17(6): 5421-5434.
[31] Dong Y X, Wang H B, Zhang Y L, et al. NIR-Ⅱ light based combinatorial management of hypertrophic scar by inducing autophagy in fibroblasts[J]. J Nanobiotechnology, 2024, 22(1): 625.
[32] Yang J L, He J, Yue T, et al. The clinical prospects and challenges of photothermal nanomaterials in myocardium recovery after myocardial infarction[J]. Front Bioeng Biotechnol, 2024, 12: 1491581.
[33] Wang X Y, Bai R R. Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases[J]. Drug Deliv, 2023, 30(1): 2256495.
[34] Zhang L H, Bei Z W, Li T, et al. An injectable conductive hydrogel with dual responsive release of rosmarinic acid improves cardiac function and promotes repair after myocardial infarction[J]. Bioact Mater, 2023, 29: 132-150.
[35] He M Q, Li Y, Zhu D S, et al. Stromal-platelet membrane-inspired nanoparticles (SPIN) for targeted heart repair[J]. Bioact Mater, 2025, 53: 45-57.
[36] Chen Q, Yu Y, Tong L, et al. Targeted delivery of TAPI-1 via biomimetic nanoparticles ameliorates post-infarct left ventricle function and remodelling[J]. Cardiovasc Res, 2025, 121(5): 760-774.
[37] Li Y Y, Yu J Q, Cheng C, et al. Platelet and erythrocyte membranes coassembled biomimetic nanoparticles for heart failure treatment[J]. ACS Nano, 2024, 18(39): 26614-26630.
[38] Lu H, Jiang Y H, Luo R, et al. Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases[J]. Mater Today Bio, 2025, 33: 101992.
[39] Yu T T, Xu Q X, Chen X, et al. Biomimetic nanomaterials in myocardial infarction treatment: harnessing bionic strategies for advanced therapeutics[J]. Mater Today Bio, 2024, 25: 100957.
[40] Wang X, Chen Y H, Zhao Z N, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction[J]. J Am Heart Assoc, 2018, 7(15): e008737.
[41] Ihnatsyeu-Kachan A, Saichuk A, Sharko O, et al. Biomimetic high-density lipoprotein nanoparticles for the delivery of nucleic acid-based therapeutics[J]. Biotechnol Adv, 2025, 83: 108606.
[42] Gong Y X, Xiao Y, Zhao C Y, et al. Ultrasmall PtIr bimetallic nanozyme treats myocardial infarction via ischemic/inflammatory cardiac microenvironment remodeling[J]. ACS Nano, 2025, 19(14): 13723-13739.
[43] Gu Z Y, Liu X L, Qi Z, et al. An antioxidant nanozyme for targeted cardiac fibrosis therapy post myocardial infarction[J]. J Nanobiotechnology, 2024, 22(1): 760.
[44] Li F Y, Liu D Z, Liu M, et al. Tregs biomimetic nanoparticle to reprogram inflammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice[J]. J Nanobiotechnology, 2022, 20(1): 251.
[45] Zhu K, Wang K, Zhang R T, et al. Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models[J]. J Nanobiotechnology, 2025, 23(1): 112.
[46] Liu Z J, Chen C, Zhang Y L, et al. Legumain in situ engineering promotes efferocytosis of CAR macrophage to treat cardiac fibrosis[J]. Adv Mater, 2025, 37(27): e2417831.
[47] Morsink M, Severino P, Luna-Ceron E, et al. Effects of electrically conductive nano-biomaterials on regulating cardiomyocyte behavior for cardiac repair and regeneration[J]. Acta Biomater, 2022, 139: 141-156.
[48] Chen C X, Ma J J, Duan S J, et al. Mitigation of ischemia/reperfusion injury via selenium nanoparticles: suppression of STAT1 to inhibit cardiomyocyte oxidative stress and inflammation[J]. Biomaterials, 2025, 318: 123119.
[49] Wang Y, Li C F, Zhao R Z, et al. CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction[J]. Theranostics, 2021, 11(13): 6315-6333.
[50] Chen S Q, Wang K, Fan Z F, et al. Modulation of anti-cardiac fibrosis immune responses by changing M2 macrophages into M1 macrophages[J]. Mol Med, 2024, 30(1): 88.
[51] Rurik J G, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury[J]. Science, 2022, 375(6576): 91-96.
[52] Esmaeili H, Patino-Guerrero A, Nelson R A Jr, et al. Engineered gold and silica nanoparticle-incorporated hydrogel scaffolds for human stem cell-derived cardiac tissue engineering[J]. ACS Biomater Sci Eng, 2024, 10(4): 2351-2366.
[53] Cheng N L, Luo Q, Yang Y Q, et al. Injectable pH responsive conductive hydrogel for intelligent delivery of metformin and exosomes to enhance cardiac repair after myocardial ischemia-reperfusion injury[J]. Adv Sci (Weinh), 2025, 12(24): e2410590.
[54] Yajima S, Lee S H, Yang J K, et al. Stromal cell-derived factor-encapsulated nanoparticles target ischemic myocardium and attenuate myocardial injury via proangiogenic effects[J]. Biomaterials, 2025, 318: 123167.
[55] Cui X L, Guo J C, Yuan P Y, et al. Bioderived nanoparticles for cardiac repair[J]. ACS Nano, 2024, 18(36): 24622-24649.
[56] Femminò S, D′Ascenzo F, Ravera F, et al. Percutaneous coronary intervention (PCI) reprograms circulating extracellular vesicles from ACS patients impairing their cardio-protective properties[J]. Int J Mol Sci, 2021, 22(19): 10270.
[57] Yang L, Mei J Q, Qiao F, et al. Randomized controlled trial assessing the efficacy and safety of a liposomal carrier for low-dose dual antiplatelet therapy (clopidogrel and aspirin) in coronary heart disease patients[J]. Clin Ther, 2025, 47(5): 339-346.
[58] Sun B X, Liu S W, Hao R B, et al. RGD-PEG-PLA delivers miR-133 to infarct lesions of acute myocardial infarction model rats for cardiac protection[J]. Pharmaceutics, 2020, 12(6): 575.
[59] Zhu K, Jiang D W, Wang K, et al. Conductive nanocomposite hydrogel and mesenchymal stem cells for the treatment of myocardial infarction and non-invasive monitoring via PET/CT[J]. J Nanobiotechnology, 2022, 20(1): 211.
[60] Sharma V, Dash S K, Manhas A, et al. Injectable hydrogel for co-delivery of 5-azacytidine in zein protein nanoparticles with stem cells for cardiac function restoration[J]. Int J Pharm, 2021, 603: 120673.
Options
Outlines

/

〈 〉